2024-09-30T19:24:30-05:00 2023-12-31 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1400 BELLEVUE WA 98004 990 2023-01-01 472231080 ALTIUS INSTITUTE FOR BIOMEDICAL SCIENCES ALTI 2062671091 2211 ELLIOTT AVENUE 600 SEATTLE WA 98121 JOHN STAMATOYANNOPOULOS PRESIDENT/SCIENTIFIC DIRECTOR 2062671091 2024-09-30 1 1 SARA ELIZABETH H JONES P00235495 4254544919 2024-09-30 2023 2024-10-15 13:58:12Z JOHN STAMATOYANNOPOULOS 2211 ELLIOTT AVENUE 600 SEATTLE WA 98121 26849381 0 X WWW.ALTIUSINSTITUTE.ORG X 2014 DE TO ADVANCE THE SCIENCE OF GENE REGULATION FOR THE BENEFIT OF HUMAN HEALTH. 4 3 156 2 0 0 42586134 25808096 12797574 189574 -128964 -275420 91821 74409 55346565 25796659 0 0 0 0 18716484 18694958 0 0 0 35448848 17297873 54165332 35992831 1181233 -10196172 39729559 26636898 13226158 10250954 26503401 16385944 X THE MISSION OF THE ALTIUS INSTITUTE FOR BIOMEDICAL SCIENCES (ALTIUS) IS TO ADVANCE THE SCIENCE OF GENE REGULATION FOR THE BENEFIT OF HUMAN HEALTH. ALTIUS AIMS TO ACCOMPLISH THIS MISSION BY RADICALLY ADVANCING BIOMEDICAL DISCOVERY THROUGH THE DEVELOPMENT AND APPLICATION OF NEW TECHNOLOGIES AND APPROACHES FOR ILLUMINATING CELL AND TISSUE FUNCTIONS IN BOTH HEALTH AND DISEASE STATES. TO ENABLE ITS MISSION, ALTIUS UTILIZES A NEW TYPE OF SCIENTIFIC AND TECHNOLOGICAL DISCOVERY ENVIRONMENT DESIGNED TO FOSTER LEAPS IN INNOVATION BY ENABLING ITS SCIENTISTS TO MOVE FROM IDEAS TO DATA FASTER THAN IN ANY OTHER ACADEMIC OR BIOTECHNOLOGY SETTING. ALTIUS CONTINUALLY STRIVES TO TRANSLATE ITS DATA AND TECHNOLOGY INTO NOVEL APPROACHES FOR DIAGNOSING AND TREATING DISEASE AND FOR IMPROVING HUMAN HEALTH. 0 1 30092006 189574 ALTIUS DIRECTLY CONDUCTS AN ACTIVE AND MULTIFACETED PROGRAM OF BASIC SCIENCE RESEARCH IN THE FIELDS OF GENETICS, GENOMICS, AND BIOTECHNOLOGY. WE CONDUCT THE MAJORITY OF RESEARCH PROGRAMS DIRECTLY IN OUR OWN LABORATORIES LOCATED IN SEATTLE, WASHINGTON, AND ALSO COLLABORATE WITH ACADEMIC RESEARCH HOSPITALS. ALTIUS AIMS TO DISCOVER, DEVELOP, AND TRANSLATE FOR CLINICAL USE BOTH DATA AND TRANSFORMATIVE TECHNOLOGIES THAT ILLUMINATE OR ENABLE THE CONTROL OF HUMAN GENES IN MEDICALLY IMPORTANT BIOLOGICAL CONTEXTS. OUR RESEARCH PROGRAMS FOCUS ON GAINING A RICHER UNDERSTANDING OF HUMAN CELLS FUNCTION IN HEALTH AND DISEASE FOR THE PURPOSE OF DEVELOPING NEW APPROACHES TO DIAGNOSIS AND THERAPY. TOWARD THESE GOALS, ALTIUS' RESEARCH PROGRAM FOCUSES ON THE DEVELOPMENT, SCALING AND TRANSLATIONAL APPLICATION OF DIVERSE TECHNOLOGY PLATFORMS, INCLUDING GENETIC AND GENOMIC ANALYSES, CELL AND GENOME ENGINEERING, SINGLE MOLECULE DNA AND CHROMATIN ANALYSIS, AND HIGH-RESOLUTION CELL IMAGING. THESE TECHNOLOGIES PROVIDE NEW WINDOWS INTO CELLULAR RESPONSES, AND THEY COLLECTIVELY OPEN NEW DOORS TO THE DISCOVERY OF NEW MEDICINES. IN RESPONSE TO THE PANDEMIC AND RELATED DISASTER DECLARATION, ALTIUS LEVERAGED ITS SCIENTIFIC EXPERTISE TO CREATE AND PROVIDE COVID-19 GENETIC TESTING SERVICES UNDER EMERGENCY CONTRACTS WITH GOVERNMENTAL AGENCIES. ALTIUS ALSO PROVIDED COVID-19 GENETIC TESTING SERVICES TO LOCAL AND NONPROFIT EDUCATIONAL ORGANIZATIONS. IN ADDITION, ALTIUS UTILIZED DATA FROM ITS GENETIC TESTING TO CONDUCT RESEARCH INTO COVID-19 EPIDEMIOLOGY AND VARIANTS IN COLLABORATION WITH GOVERNMENTAL AGENCIES AND ACADEMIC INSTITUTIONS. ALTIUS CEASED ITS COVID TESTING OPERATIONS IN MARCH 2023. 30092006 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 0 1 0 0 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 23 0 156 1 0 0 0 0 0 0 0 0 0 0 0 0 X 4 3 0 0 0 0 1 1 1 1 1 0 0 0 1 1 1 1 1 1 0 0 X CHANYA SWARTZ 2062671091 2211 ELLIOTT AVENUE SUITE 600 SEATTLE WA 98121 JOHN STAMATOYANNOPOULOS SCIENTIFIC DIRECTOR & TREASURER 40.00 X X 885000 0 49349 PETER HANDRINOS BOARD MEMBER 2.00 X 50000 0 0 HARRY DIETZ BOARD MEMBER 1.00 X 50000 0 0 ERIK INGELSSON BOARD MEMBER 0.50 X 0 0 0 JOHN LEPORE BOARD MEMBER (PART YEAR) 0.50 X 0 0 0 LORI TONNES GEN. COUNSEL & SECRETARY (THRU 6/23) 40.00 X 174494 0 22164 THOMAS GROHMAN CORPORATE SECRETARY 1.00 X 11762 0 0 ALISTER FUNNELL DEPUTY DIRECTOR 40.00 X 600000 0 55152 CHAD LUNDBERG CHIEF OF STAFF 40.00 X 450000 0 53663 MICHAEL COCKRILL CHIEF TECHNOLOGY OFFICER 40.00 X 400000 0 71287 JEFFREY VIERSTRA PRINCIPAL INVESTIGATOR 40.00 X 350000 0 58990 WILLIAM KERWIM PRINCIPAL INVESTIGATOR 40.00 X 285000 0 56639 3256256 0 367244 45 0 1 0 CLARK NUBER PS 10900 NE 4TH ST UNIT 1400 BELLEVUE WA 98004 AUDIT, TAX & CONSULTING 166680 BOZICEVIC FIELD & FRANCIS LLP 101 SECOND ST SUITE 1250 SAN FRANCISCO CA 94105 LEGAL CONSULTING 131222 KEITH GROCHOW 1425 BROADWAY SEATTLE WA 98122 SOFTWARE ENGINEERING 120650 DAVIS WRIGHT TREMAINE LLP 920 FIFTH AVENUE SUITE 3300 SEATTLE WA 98104 LEGAL CONSULTING 105527 4 1448711 24359385 25808096 COVID LAB RESEARCH 541380 189574 189574 189574 414802 414802 28625 28625 362500 1052722 -690222 -690222 -690222 REBATES 900099 28196 28196 FOREIGN EXCHANGE GAIN 900099 17588 17588 45784 25796659 189574 0 -201011 X 1242769 934349 308420 14075243 11871270 2203973 1151807 961759 190048 1089048 922317 166731 1136091 948636 187455 494488 494488 259865 259865 1141669 308375 833294 468397 19681 448716 1978001 1750531 227470 3370081 2990703 379378 255012 255012 29158 29158 3972012 3972012 138838 138838 LAB SUPPLIES 3475143 3475143 RESEARCH & DEVELOPMENT 1342195 1342195 BUSINESS TAX & LICENSES 273014 547 272467 RESEARCH COLLABORATION 100000 100000 35992831 30092006 5900825 0 1538455 1123185 12665062 3040443 1749718 1094073 885540 34647 1447796 1423124 28036918 16056684 13088404 11980234 16225 16225 8338359 7924967 39729559 26636898 4283083 2848980 699386 0 8243689 7401974 13226158 10250954 X 26503401 16385944 26503401 16385944 39729559 26636898 X -10196172 78715 X 0 1 X 1 1 1 X BRIGHAM AND WOMEN'S HOSPITAL BOSTON MA MOUNT SINAI SCHOOL OF MEDICINE NEW YORK NY UNIVERSITY OF WASHINGTON MEDICAL CENTER SEATTLE WA FRED HUTCH CANCER CENTER SEATTLE WA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 7894034 3053741 4840293 18512565 11941884 6570681 1630319 1061059 569260 11980234 SECURITY DEPOSITS 58200 RIGHT OF USE ASSET 7166767 LINE OF CREDIT 700000 7924967 LEASE LIABILITY 7401974 7401974 25796659 0 25796659 0 25796659 35992831 0 35992831 0 35992831 EUROPE (INCLUDING ICELAND & GREENLAND) 0 1 PROGRAM SERVICES RESEARCH, EMPLOYEE COMPENSATION 275000 0 1 0 0 0 1 275000 0 275000 0 0 0 0 0 0 X 1 1 X X X X X 0 0 0 0 0 0 0 0 0 JOHN STAMATOYANNOPOULOS SCIENTIFIC DIRECTOR & TREASURER 885000 0 0 0 0 0 44250 0 5099 0 934349 0 0 0 ALISTER FUNNELL DEPUTY DIRECTOR 600000 0 0 0 0 0 44250 0 10902 0 655152 0 0 0 CHAD LUNDBERG CHIEF OF STAFF 450000 0 0 0 0 0 44250 0 9413 0 503663 0 0 0 MICHAEL COCKRILL CHIEF TECHNOLOGY OFFICER 400000 0 0 0 0 0 44250 0 27037 0 471287 0 0 0 JEFFREY VIERSTRA PRINCIPAL INVESTIGATOR 350000 0 0 0 0 0 43250 0 15740 0 408990 0 0 0 WILLIAM KERWIM PRINCIPAL INVESTIGATOR 285000 0 0 0 0 0 39750 0 16889 0 341639 0 0 0 LORI TONNES GEN. COUNSEL & SECRETARY (THRU 6/23) 174494 0 0 0 0 0 18525 0 3639 0 196658 0 0 0 PART I, LINE 1A JOHN STAMATOYANNOPOULOS PARTICIPATED IN FIRST CLASS TRAVEL. THIS WAS NOT TREATED AS TAXABLE INCOME TO THE INDIVIDUAL. FORM 990, PART I, LINE 6: THE VOLUNTEER COUNT IS MADE UP OF TWO UNCOMPENSATED BOARD MEMBERS. FORM 990, PART III, LINE 3 OPERATIONS OF COVID-19 TESTING SERVICES CEASED MARCH 2023. SEE PART III, LINE 4A FOR MORE DETAILS. FORM 990, PART VI, SECTION A, LINE 6 THE ORGANIZATION HAS ONE CLASS OF MEMBERSHIP WHICH INCLUDES TWO MEMBERS, DR. JOHN STAMATOYANNOPOULOS (OR HIS DESIGNEE) AND GLAXOSMITHKLINE LLC. FORM 990, PART VI, SECTION A, LINE 7A THE MEMBERS OF THE ORGANIZATION ARE ENTITLED TO ELECT DIRECTORS OF THE BOARD AND REMOVE ONLY DIRECTORS WHICH THEY HAVE APPOINTED. FORM 990, PART VI, SECTION A, LINE 7B THE GLAXOSMITHKLINE LLC MEMBER MAY ELECT AND REMOVE GLAXOSMITHKLINE LLC DIRECTORS OF THE BOARD WHILE JOHN STAMATOYANNOPOULOS AS A MEMBER MAY ELECT AND REMOVE JOHN STAMATOYANNOPOULOS DIRECTORS OF THE BOARD. COMMON DIRECTORS OF THE BOARD ARE ELECTED AND REMOVED BY UNANIMOUS ACTION OF JOHN STAMATOYANNOPOULOS AND GLAXOSMITHKLINE LLC MEMBERS. FORM 990, PART VI, SECTION B, LINE 11B THE DIRECTOR OF FINANCE, PRESIDENT/SCIENTIFIC DIRECTOR, AND AUDIT COMMITTEE WILL REVIEW THE FORM 990 PRIOR TO ITS SUBMISSION TO THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION'S CONFLICT OF INTEREST POLICY REQUIRES COVERED PERSONS, DEFINED AS ANY DIRECTOR, OFFICER, OR MEMBER OF A COMMITTEE OF THE BOARD OF DIRECTORS, TO COMPLETE AND SIGN AN ANNUAL CONFLICT OF INTEREST QUESTIONNAIRE. THE QUESTIONNAIRE REQUIRES DISCLOSURE OF ANY POTENTIAL OR ACTUAL CONFLICTS OF INTEREST AND IS SIGNED BY THE COVERED PERSON, AFFIRMING THAT THE INDIVIDUAL HAS RECEIVED A COPY OF, READ, UNDERSTANDS, AND WILL COMPLY WITH THE ORGANIZATION'S CONFLICT OF INTEREST POLICY. IF A POTENTIAL OR ACTUAL CONFLICT OF INTEREST ARISES, THE INDIVIDUAL MUST RECUSE HIMSELF OR HERSELF FROM VOTING ON THE MATTER AND MUST NOT BE PRESENT WHEN ANY SUCH VOTE IS TAKEN. THE BOARD OF DIRECTORS EVALUATES ALL DISCLOSURES REPORTED TO DETERMINE WHETHER AN ACTUAL CONFLICT OF INTEREST EXISTS. POTENTIAL OR ACTUAL CONFLICTS OF INTEREST ARE DOCUMENTED IN THE MINUTES OF MEETINGS OF THE BOARD OF DIRECTORS AND COMMITTEE'S OF THE BOARD. FORM 990, PART VI, SECTION B, LINE 15A A COMPENSATION STUDY WAS CONDUCTED BY AN OUTSIDE CONSULTANT IN 2023 TO DETERMINE THE COMPENSATION FOR THE PRESIDENT AND SENIOR EXECUTIVES. THE COMPENSATION STUDY WAS APPROVED BY THE COMPENSATION COMMITTEE. THE STUDY IS EFFECTIVE FOR 2024. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G CONTRACT SERVICES: PROGRAM SERVICE EXPENSES 28,764. MANAGEMENT AND GENERAL EXPENSES 508,534. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 537,298. RECRUITING COSTS: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 127,625. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 127,625. BOARD FEES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 125,000. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 125,000. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 279,611. MANAGEMENT AND GENERAL EXPENSES 72,135. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 351,746. PART IX, FUNCTIONAL EXPENSE ALLOCATION: ALL EXPENSES ASSOCIATED WITH OBTAINING GRANTS ARE INCLUDED IN PROGRAM AND GENERAL AND ADMINISTRATIVE EXPENSES AS ALLOWED UNDER THE INDIRECT COST RECOVERY PROVISIONS OF THE GRANT AGREEMENT. FORM 990, PART XI, LINE 9: ADD'L REVENUE RECOGNIZED ON PY AUDITED FINANCIALS AFTER FILING OF FORM 990 78,715.